Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Rated “Hold” by Sell-Side Analysts

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) have received a consensus recommendation of “Hold” from the twenty-three research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, twelve have issued a hold recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $27.18.

Several equities analysts have recently issued reports on TNDM shares. Barclays lifted their price objective on Tandem Diabetes Care from $18.00 to $20.00 and gave the company an “equal weight” rating in a research note on Friday, November 6th. Citigroup dropped their price objective on shares of Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, September 30th. UBS Group began coverage on shares of Tandem Diabetes Care in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $18.00 price objective on the stock. Truist Financial reduced their price objective on shares of Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, September 24th. Finally, Mizuho set a $20.00 price objective on shares of Tandem Diabetes Care in a research report on Friday, November 6th.

Tandem Diabetes Care Stock Performance

NASDAQ TNDM opened at $18.77 on Friday. The company has a debt-to-equity ratio of 4.47, a current ratio of 3.20 and a quick ratio of 2.65. The company has a market cap of $1.31 billion, a P/E ratio of -26.07 and a beta of 1.59. The stock has a 50-day moving average of $17.47 and a two-hundred day moving average of $18.85. Tandem Diabetes Care has a 1-year low of $12.26 and a 1-year high of $29.65.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, November 5th. The medical device company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.15. The business had revenue of $283.69 million during the quarter, compared to the consensus estimate of $265.85 million. Tandem Diabetes Care had a negative net margin of 4.58% and a negative return on equity of 35.61%. The company’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.31) earnings per share. As a group, analysts anticipate that Tandem Diabetes Care will post -0.61 EPS for the current year.

Insider Transactions at Tandem Diabetes Care

In other news, Director Christopher J. Twomey sold 1,700 shares of the company’s stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total transaction of $32,555.00. Following the completion of the transaction, the director directly owned 24,434 shares of the company’s stock, valued at approximately $467,911.10. This represents a 6.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Public Sector Pension Investment Board boosted its holdings in Tandem Diabetes Care by 0.7% in the third quarter. Public Sector Pension Investment Board now owns 237,049 shares of the medical device company’s stock valued at $3,891,000 after purchasing an additional 1,591 shares in the last quarter. Sterling Capital Management LLC raised its holdings in Tandem Diabetes Care by 849.0% during the third quarter. Sterling Capital Management LLC now owns 2,325 shares of the medical device company’s stock worth $38,000 after purchasing an additional 2,080 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in Tandem Diabetes Care during the second quarter worth approximately $33,000. 180 Wealth Advisors LLC raised its holdings in Tandem Diabetes Care by 17.3% during the first quarter. 180 Wealth Advisors LLC now owns 15,763 shares of the medical device company’s stock worth $302,000 after purchasing an additional 2,320 shares in the last quarter. Finally, Summit Global Investments lifted its position in shares of Tandem Diabetes Care by 13.9% during the 3rd quarter. Summit Global Investments now owns 24,753 shares of the medical device company’s stock worth $404,000 after buying an additional 3,017 shares during the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.